<DOC>
	<DOCNO>NCT01402271</DOCNO>
	<brief_summary>RATIONALE : Pazopanib hydrochloride may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , paclitaxel carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This randomized phase I/II trial study side effect best dose pazopanib hydrochloride give together paclitaxel carboplatin treat patient refractory resistant ovarian epithelial cancer , fallopian tube cancer , peritoneal cancer .</brief_summary>
	<brief_title>Pazopanib Hydrochloride , Paclitaxel , Carboplatin Treating Patients With Refractory Resistant Ovarian Epithelial Cancer , Fallopian Tube Cancer , Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum-tolerated dose pazopanib hydrochloride combination paclitaxel carboplatin patient platinum-refractory -resistant ovarian epithelial , fallopian tube , peritoneal carcinoma . ( Phase I ) - To determine progression-free survival ( PFS ) 1 year accord RECIST 1.1 patient . ( Phase II ) Secondary - To determine safety adverse event profile patient . ( Phase I phase II ) - To determine pharmacokinetics ( PK ) regimen use intensive sampling . ( Phase I ) - To determine PK interaction ( , kind PK interaction ) carboplatin paclitaxel well pazopanib hydrochloride . ( Phase I ) - To determine response rate ( RR ) patient . ( Phase I ) - To determine evaluate predictive biomarkers . ( Phase I phase II ) - To determine RR , overall survival ( OS ) , PFS patient . ( Phase II ) OUTLINE : This multicenter , phase I , dose-escalation study carboplatin , paclitaxel , pazopanib hydrochloride follow phase II randomize study . - Phase I : Patients receive paclitaxel IV 1 hour follow carboplatin IV 30 minute day 1 . Patients also receive oral pazopanib hydrochloride* daily day 2-7 . Treatment repeat every week 18 courses** . Patients continue receive oral pazopanib hydrochloride daily absence disease progression unacceptable toxicity . NOTE : *Pazopanib hydrochloride start course 2 order evaluate pharmacokinetic paclitaxel carboplatin prior pazopanib hydrochloride administration . - Phase II : Patients stratify accord center , disease status ( platinum-refractory v -resistant ) number prior line treatment ( 1 vs 1 ) . Patients randomize 2:1 ratio ( arm II [ experimental arm ] : arm I [ standard arm ] ) 1 2 treatment arm . - Arm I ( standard arm ) : Patients receive paclitaxel IV 1 hour carboplatin IV 30 minute day 1 . Treatment repeat every week 18 course . - Arm II ( experimental arm ) : Patients receive paclitaxel IV 1 hour carboplatin IV 30 minute day 1 . Patients also receive oral pazopanib hydrochloride daily day 2-7 . Treatment repeat every week 18 courses** . Patients continue receive oral pazopanib hydrochloride daily absence disease progression unacceptable toxicity . NOTE : **After course 9 , chemotherapy interrupt 1 week . Blood sample collect patient periodically pharmacokinetic biomarker study . After completion study treatment , patient follow 3 week , every 3 month 2 year , every 6 month 3 year .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial , fallopian tube , peritoneal carcinoma Recurrent disease Received least 1 prior platinum treatment develop platinumrefractory disease ( i.e. , progression within 4 week platinum administration ) platinumresistant disease ( i.e. , progression within 6 month last platinum dose ) There restriction number prior line treatment Nonplatinum treatment allow proven platinumresistance refractory disease Evaluable ( measurable nonmeasurable ) disease accord RECIST version 1.1 criterion Patients refractory disease weekly paclitaxel carboplatin regimen exclude ( phase II ) No know gastrointestinal intraluminal metastatic lesion risk bleed No known endobronchial lesion and/or lesion infiltrate major pulmonary vessel No know brain metastasis leptomeningeal disease PATIENT CHARACTERISTICS : WHO performance status 02 Absolute neutrophil count ≥ 1.5 x 10^9/L Hemoglobin ≥ 9 g/dL Platelet count ≥ 100 x 10^9/L PT , aPTT , INR ≤ 1.2 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN* ALT AST ≤ 2.5 time ULN* Serum creatinine ≤ 1.5 mg/dL OR calculate creatinine clearance ≥ 50 mL/min Urine protein creatinine ratio &lt; 1 OR 24hour urine protein &lt; 1 g Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study therapy No prior primary recurrent malignancy treat within past 2 year except completely resect nonmelanomatous skin carcinoma successfully treat carcinoma situ skin uterine cervix No know immediate delay hypersensitivity reaction idiosyncrasy drug similar related paclitaxel , carboplatin , pazopanib hydrochloride Able receive infusion paclitaxel carboplatin Able swallow pazopanib hydrochloride tablets No unstable serious condition ( e.g. , uncontrolled infection require systemic therapy ) No history follow cardiovascular condition within past 6 month : Myocardial infarction Unstable angina Symptomatic peripheral vascular disease NYHA class IIIIV congestive heart failure LVEF &gt; 50 % assess ultrasound MUGA scan , clinically indicate No inadequately control hypertension ( SBP ≥ 140 mm Hg DBP ≥ 90 mm Hg ) Initiation adjustment blood pressure medication permit prior study entry No prolong correct QT interval ( QTc ) define &gt; 480 msec use Bazett formula No history cerebrovascular accident within past 6 month , include follow : Transient ischemic attack Pulmonary embolism Untreated deep venous thrombosis ( DVT ) Patients recent DVT treat therapeutic anticoagulating agent least 6 week eligible No evidence active bleeding bleed diathesis No clinically significant gastrointestinal ( GI ) tract abnormality may increase risk GI bleed include , limited , follow : Active peptic ulcer disease Inflammatory bowel disease ( e.g. , ulcerative colitis Crohn disease ) No history bowel obstruction ( exclude postoperative ( i.e . within 4 week post surgery ) ) whole prior history patient , GI condition increase risk perforation clear infiltration rectosigmoid , colon small bowel . No clinically significant GI abnormality may affect absorption investigational product include , limited , follow : Malabsorption syndrome Major resection stomach small bowel No hemoptysis excess 2.5 mL ( onehalf teaspoon ) within 8 week prior first dose study drug No psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule No trauma within past 28 day No prior nonhealing wound , fracture , ulcer PRIOR CONCURRENT THERAPY : See Disease Characteristics No ongoing toxicity prior anticancer therapy &gt; grade 1 and/or progress severity , except alopecia ≤ grade 2 peripheral neuropathy No cardiac angioplasty stenting within past 6 month No coronary artery bypass graft surgery within past 6 month At least 14 day since prior radiotherapy , surgery , tumor embolization , chemotherapy , immunotherapy , biologic therapy , investigational therapy , hormonal therapy ( 28 day drug longer halflife ) At least 14 day since prior ( 28 day drug longer halflife ) concurrent prohibit medication At least 28 day since prior major surgery ( procedure catheter placement diagnostic endoscopic procedure consider major )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent fallopian tube cancer</keyword>
	<keyword>recurrent primary peritoneal cavity cancer</keyword>
</DOC>